Summary : This figure presents the 2024 recommended immunization schedule for children and adolescents in the United States, showing the timing and sequence of vaccines from birth through 18 years of age. It uses a Gantt-style chart to indicate when each vaccine dose should be administered, including notes for special circumstances and seasonal recommendations. gantt chart: # Title & Axes : • Title: "Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2024" • X-axis: Age intervals (Birth, 1 mo, 2 mos, 4 mos, 6 mos, 9 mos, 12 mos, 15 mos, 18 mos, 19–23 mos, 2–3 yrs, 4–6 yrs, 7–10 yrs, 11–12 yrs, 13–15 yrs, 16 yrs, 17–18 yrs) • Y-axis: Vaccine and other immunizing agents (listed in rows) # Vaccine Rows : • Respiratory syncytial virus (RSV-mAb, nirsevimab, clesrovimab) • Hepatitis B (HepB) • Rotavirus (RV: RV1, RV5) • Diphtheria, tetanus, and acellular pertussis (DTaP <7 yrs) • Haemophilus influenzae type b (Hib) • Pneumococcal conjugate (PCV15, PCV20) • Inactivated poliovirus (IPV) • COVID-19 (1vCOV-mRNA, 1vCOV-aPS) • Influenza • Measles, mumps, and rubella (MMR) • Varicella (VAR) • Hepatitis A (HepA) • Tetanus, diphtheria, and acellular pertussis (Tdap ≥7 yrs) • Human papillomavirus (HPV) • Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2 years) • Meningococcal B (MenB-4C, MenB-FHbp) • Respiratory syncytial virus vaccine (RSV [Abrysvo]) • Dengue (DEN4CYD: 9–16 yrs) • Mpox # Dose Timing & Colour Coding : • Blue ovals: Standard recommended doses (e.g., "1st dose", "2nd dose", "3rd dose", etc.) • Purple bars: Time windows for additional or catch-up doses • Orange bars/boxes: Special notes, seasonal recommendations, or age-specific guidance (e.g., "See Notes", "Seasonal administration during pregnancy if not previously vaccinated", "Seropositive in areas with endemic dengue") • Dotted blue bars: Future or annual recommendations (e.g., COVID-19 vaccine for 2025–2026) # Design Encodings : • Each vaccine row uses a combination of blue, purple, and orange to distinguish standard, catch-up, and special/seasonal recommendations. • Notes and exceptions are highlighted in orange for visibility. • Overlapping bars indicate flexibility or alternative schedules for certain vaccines. # Analysis : • The schedule is densely packed in the first two years of life, with most vaccines administered in multiple doses during infancy and early childhood. • Several vaccines (e.g., DTaP, Hib, PCV, IPV) have booster doses in later childhood. • Annual or seasonal vaccines (e.g., Influenza, COVID-19) are indicated for ongoing administration. • Special recommendations (e.g., RSV, Dengue, Meningococcal, HPV) are highlighted for specific age groups or risk factors. • The chart visually emphasizes the importance of timely vaccination and provides clear guidance for catch-up and special circumstances.

Summary : This figure is a comprehensive reference chart summarizing vaccine and immunizing agent recommendations for children and adolescents with various medical conditions and special situations. It uses color-coded bars and patterns to indicate which vaccines are recommended, contraindicated, or require special consideration for each condition. table: # Vaccine Recommendations for Children and Adolescents with Medical Conditions and Special Situations : ## Structure : • The leftmost column lists vaccines and other immunizing agents (e.g., RSV-mAb, Hepatitis B, Rotavirus, DTaP/Tdap, Hib, Pneumococcal, IPV, COVID-19, Influenza, LAIV3, MMR, VAR, Hepatitis A, HPV, MenACWY, MenB, RSV, Dengue, Mpox). • The top row lists medical conditions and special situations: Pregnancy, Immunocompromised (excluding HIV), HIV infection (with CD4 count subcategories), CSF leak or cochlear implant, Asplenia or persistent complement component deficiencies, Heart disease or chronic lung disease (CLD), Kidney failure/ESRD/on dialysis, Chronic liver disease, Diabetes. ## Color and Pattern Legend : • Solid blue bar: Recommended for all persons in this risk group. • Solid red bar: Contraindicated. • Red diagonal stripes: Precaution or special consideration. • Purple outline: Recommended for some persons in this risk group. • Orange bar: Recommended for persons with additional risk factors or in certain situations. • Notes and asterisks indicate further details or exceptions. ## Key Data Points : • RSV-mAb is recommended for most groups, with special notes for immunocompromised, HIV, and CLD. • Hepatitis B, DTaP/Tdap, Hib, Pneumococcal, IPV, COVID-19, Influenza (inactivated), Hepatitis A, HPV, MenACWY, MenB are broadly recommended (solid blue) for most risk groups. • Rotavirus, LAIV3, MMR, VAR are contraindicated (solid red) in immunocompromised and HIV-infected children with low CD4 counts. • LAIV3 is contraindicated in pregnancy, immunocompromised, and children with asthma/wheezing (2–4 years). • COVID-19, Influenza, and Dengue have special notes or are recommended only in certain situations. • Mpox is recommended for some groups (orange bar) with notes for details. ## Design Encodings : • Each cell uses a color or pattern to indicate recommendation status. • Asterisks and notes provide additional guidance for specific vaccines or conditions. • The chart is organized for quick cross-reference by vaccine and condition. Analysis : • Most inactivated vaccines are broadly recommended for children with chronic conditions or immunocompromised states. • Live vaccines (e.g., LAIV3, MMR, VAR, Rotavirus) are generally contraindicated in immunocompromised and certain HIV-infected children. • Pregnancy, immunocompromised status, and specific organ dysfunctions (e.g., asplenia, kidney failure) require special consideration for several vaccines. • The chart highlights the complexity of vaccine recommendations in special populations and the importance of individualized assessment.

A multi-panel medical infographic illustrating the prevention, diagnosis, and monitoring of HPV-attributable oropharyngeal cancer (HPV-AOC). The top section features two anatomical illustrations of an open mouth: the first shows a brown, exophytic mass on the right palatine tonsil representing tumor presentation; the second shows the same region after treatment with the mass absent. Arrows indicate clinical progression from HPV infection to cancer development, inhibited by primary prevention via HPV vaccination. The bottom section details diagnostic pathways: (1) Early detection methods including Anti-HPV-16 E6 antibody testing and detection of cell-free DNA in blood. (2) Pre-treatment annotation protocols, identifying the standard of care as tumor tissue testing for p16 overexpression and HPV DNA/mRNA, alongside alternative methods like oral rinses and lesion swabbing. (3) Tertiary prevention and monitoring through the detection of HPV persistence in oral rinses and cell-free DNA in blood post-treatment to predict cancer recurrence. The diagram utilizes icons of blood vials, swabs, and histology slides to represent various diagnostic modalities.